Figure 4.

Sitagliptin, alone or in combination with other diabetes medications, can promote glycemic control in kidney transplant recipients with NODAT. Diabetes control at baseline compared to end of followup in (a) patients maintained on sitagliptin alone (n = 9, 31.8 ± 18.7 months of followup), (b) patients maintained on sitagliptin in combination with other diabetes medication(s) (n = 8, 44.9 ± 10.9 months of followup), and (c) patients who discontinued sitagliptin in favor of other diabetes medications (n = 5, 14 ± 4.2 months of followup). (d) Comparison of baseline hemoglobin A1c in sitagliptin alone patients (n = 9) compared to patients who discontinued sitagliptin in favor of other diabetes medications (n = 5). Data shown as mean ± SD.